The startup has partnered with Eli Lilly and enjoys the backing of some of Silicon Valley's most influential VCs.
Nvidia and Eli Lilly and Co. are partnering to create an artificial intelligence lab in the San Francisco Bay Area to ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
In just three months, Phlow and Enveda generated and analyzed nearly 20,000 unique reactions, creating one of the largest high-quality datasets of its kind. The resulting uniform dataset is ...
Please provide your email address to receive an email when new articles are posted on . AIM-MASH AI Assist is the first AI drug development tool to be qualified by the FDA. The tool is designed to ...
The Chosun Ilbo on MSN
NVIDIA, Eli Lilly partner on physical AI drug development
On the 12th (local time), the ‘JP Morgan Healthcare Conference’ opened in San Francisco, U.S. The biggest topic at this ...
Fatima Sabar, CEO and co-founder of Bluenote, says artificial intelligence is poised to revolutionize drug development by reducing administrative burdens and allowing scientists to focus on innovation ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their clinical trials. The agency gave a green light to the AI-Based Histologic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback